PK150, a new antibiotic derived from the anti-cancer drug sorafenib, is active against MRSA, kills persister cells, reduces biofilms, and does not induce resistance under laboratory conditions. Mode-of-action analysis unveiled two independent protein targets: the inhibition of menaquinone methyltransferase (MenG) and activation of SpsB, a signal peptidase in the secretory pathway. MenG, but not SpsB, was further found to be a molecular target of the structurally related disinfectant triclocarban.
«
PK150, a new antibiotic derived from the anti-cancer drug sorafenib, is active against MRSA, kills persister cells, reduces biofilms, and does not induce resistance under laboratory conditions. Mode-of-action analysis unveiled two independent protein targets: the inhibition of menaquinone methyltransferase (MenG) and activation of SpsB, a signal peptidase in the secretory pathway. MenG, but not SpsB, was further found to be a molecular target of the structurally related disinfectant triclocarban...
»